Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 71

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 71
---
 or warranty), and (ii) the                                       
 Company has delivered a certificate confirming same to the Purchaser, executed by an officer of the Company (without personal liability) addressed to the Purchaser and dated the Effective Date. |

| (b) | Performance of Covenants by the Company. The Company has fulfilled or complied in all material respects                                                                                                                                         
 with the covenants of the Company contained in this Agreement to be fulfilled or complied with by it on or prior to the Effective Time, and the Company has delivered a certificate confirming same to the Purchaser, executed by an officer of 
 the Company (without personal liability) addressed to the Purchaser and dated the Effective Date.                                                                                                                                               |

| (c) | No Legal Action. No Proceeding shall be pending or threatened by any Governmental Entity in any                                                                                                                                            
 jurisdiction that is reasonably likely to (i) cease trade, enjoin, prohibit, or impose any limitations, damages, or conditions on, the Purchaser’s ability to acquire, hold, or exercise full rights of ownership over, any Common Shares, 
 including the right to vote the Common Shares, or (ii) prohibit or enjoin the Company or the Purchaser from consummating the Arrangement.                                                                                                  |

| (d) | Material Adverse Change. There shall have not occurred a Material Adverse Change and the Company has                                                                                  
 delivered a certificate confirming same to the Purchaser, executed by an officer of the Company (without personal liability) addressed to the Purchaser and dated the Effective Date. |

| (e) | Dissent Rights. Dissent Rights have not been exercised with respect to more than 5% of the issued and 
 outstanding Common Shares.                                                                            |

| (f) | Closing Net Cash. The Closing Net Cash shall be greater than or equal to zero and, in furtherance and                                                                                                                                         
 not in limitation of Section 7.1(a), neither Purchaser, Parent nor any other person on their behalf shall be required to make a payment under the Plan of Arrangement (whether pursuant to Section 2.9 or otherwise), except as Purchaser may 
 be required to pay Fair Value to any Dissenting Shareholder in accordance with the Plan of Arrangement.                                                                                                                                       |

| (g) | Deposit of Consideration. The Company shall have complied with its obligations under Section 2.9. |

| 7.3 | Additional Conditions Precedent to the Obligations of the Company |

The Company is not required to complete the Arrangement unless each